About us

AnaMar AB is a pharmaceutical company that specializes in the development of 5-HT2B receptor antagonists for various types of fibrotic diseases.

Our project portfolio includes the candidate drug AM1476, which is currently in planning of a Phase II clinical study. In addition, we have a portfolio of additional patented highly selective, orally bioavailable, peripherally-acting 5-HT2B receptor antagonists.

AnaMar AB is a privately held company.